GEMINA’S RECENT INVESTMENT INTO RAPIVD SEES IMMEDIATE PROGRESS

December 13, 2022

GEMINA LABORATORIES LTD. 

News Release 

GEMINA’S RECENT INVESTMENT INTO RAPIVD SEES IMMEDIATE PROGRESS 

December 13, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to announce that RAPIvD Limited (“RAPIvD”) has met an important  regulatory milestone. 

On December 7, 2022, Gemina announced that it had entered into a definitive share exchange agreement  to acquire 19% of the issued and outstanding shares of RAPIvD with the option, subject to certain  conditions, to acquire all of the remaining issued and outstanding RAPIvD shares. Today, Gemina is able to announce that RAPIvD has achieved a significant certification, namely the International Organization  for Standardization ISO 13485 medical devices standards for ‘contract development and manufacture of  lateral flow assays for IVD’ ("in vitro diagnostics”). The certification follows a rigorous operational audit  by the British Standards Institution (BSI) and enables RAPIvD to manufacture lateral flow assays in-house. 

Dr Robert Porter, RAPIvD’s founder and CEO said. “Obtaining ISO 13485 certification means that we have  passed another strategic milestone in our continued development. We set up our systems to meet the  industry’s best-practice standards and to have this ratified by the BSI and ISO is hugely beneficial. It  recognises the hard work and application of our staff and assures our partners, customers and others in  the supply chain, that we operate quality management processes and deliver high standards in everything  we do”.  

Brian Firth, Gemina’s CEO added “I’d like to pass on my congratulations to the RAPIvD team. This level of  certification is no small achievement and adds significantly to our combined capacity to take lateral flow  products into in-house manufacturing”. 

On Behalf of the Board of Directors 

John Davies 

Chairman 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

Brian Firth 

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.